Cargando…

Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction

AIMS: The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have foc...

Descripción completa

Detalles Bibliográficos
Autores principales: Funada, Daisuke, Matsumoto, Toshihiko, Tanibuchi, Yuko, Kawasoe, Yasunari, Sakakibara, Satoru, Naruse, Nobuya, Ikeda, Shunichiro, Sunami, Takashi, Muto, Takeo, Cho, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292321/
https://www.ncbi.nlm.nih.gov/pubmed/30968601
http://dx.doi.org/10.1002/npr2.12053
_version_ 1783546088191426560
author Funada, Daisuke
Matsumoto, Toshihiko
Tanibuchi, Yuko
Kawasoe, Yasunari
Sakakibara, Satoru
Naruse, Nobuya
Ikeda, Shunichiro
Sunami, Takashi
Muto, Takeo
Cho, Tetsuji
author_facet Funada, Daisuke
Matsumoto, Toshihiko
Tanibuchi, Yuko
Kawasoe, Yasunari
Sakakibara, Satoru
Naruse, Nobuya
Ikeda, Shunichiro
Sunami, Takashi
Muto, Takeo
Cho, Tetsuji
author_sort Funada, Daisuke
collection PubMed
description AIMS: The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS‐related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS. METHODS: Subjects (n = 864) were patients with NPS‐related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records. RESULTS: Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3‐year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001). CONCLUSION: The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased.
format Online
Article
Text
id pubmed-7292321
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72923212020-12-08 Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction Funada, Daisuke Matsumoto, Toshihiko Tanibuchi, Yuko Kawasoe, Yasunari Sakakibara, Satoru Naruse, Nobuya Ikeda, Shunichiro Sunami, Takashi Muto, Takeo Cho, Tetsuji Neuropsychopharmacol Rep Original Articles AIMS: The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS‐related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS. METHODS: Subjects (n = 864) were patients with NPS‐related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records. RESULTS: Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3‐year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001). CONCLUSION: The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased. John Wiley and Sons Inc. 2019-04-09 /pmc/articles/PMC7292321/ /pubmed/30968601 http://dx.doi.org/10.1002/npr2.12053 Text en © 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Funada, Daisuke
Matsumoto, Toshihiko
Tanibuchi, Yuko
Kawasoe, Yasunari
Sakakibara, Satoru
Naruse, Nobuya
Ikeda, Shunichiro
Sunami, Takashi
Muto, Takeo
Cho, Tetsuji
Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title_full Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title_fullStr Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title_full_unstemmed Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title_short Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction
title_sort changes of clinical symptoms in patients with new psychoactive substance (nps)‐related disorders from fiscal year 2012 to 2014: a study in hospitals specializing in the treatment of addiction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292321/
https://www.ncbi.nlm.nih.gov/pubmed/30968601
http://dx.doi.org/10.1002/npr2.12053
work_keys_str_mv AT funadadaisuke changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT matsumototoshihiko changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT tanibuchiyuko changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT kawasoeyasunari changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT sakakibarasatoru changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT narusenobuya changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT ikedashunichiro changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT sunamitakashi changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT mutotakeo changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction
AT chotetsuji changesofclinicalsymptomsinpatientswithnewpsychoactivesubstancenpsrelateddisordersfromfiscalyear2012to2014astudyinhospitalsspecializinginthetreatmentofaddiction